W. Gommeren

发表

Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.

J. Leysen, G. Haegeman, I. van de Weyer, 1996, Molecular pharmacology.

Seasonal Variation in Platelet [3H]Paroxetine Binding in Healthy Volunteers

J. Leysen, M. Maes, S. Scharpe, 1996, Neuropsychopharmacology.

Distinction between adrenergic and serotonergic receptor subtypes: specificity of drugs and absence of cooperative interactions between adrenergic and serotonergic receptor binding sites.

J. Leysen, W. Gommeren, P. van Gompel, 1988, Journal of cardiovascular pharmacology.

Receptor interactions of dopamine and serotonin antagonists: binding in vitro and in vivo and receptor regulation.

J. Leysen, P. Janssen, W. Gommeren, 1988, Psychopharmacology series.

Chronic neuroleptic treatment specifically alters the number of dopamine receptors in rat brain.

C. Marsden, J. Leysen, P. Jenner, 1981, Life sciences.

Distinction between dopaminergic and serotonergic components of neuroleptic binding sites in limbic brain areas.

J. Leysen, P. Laduron, W. Gommeren, 1979, Biochemical pharmacology.

In vitro binding properties of 3H-sufentanil, a superior ligand for the mu-opiate receptor.

J. Leysen, W. Gommeren, 1982, Archives internationales de pharmacodynamie et de therapie.

Structure of the Human Serotonin 5‐HT4 Receptor Gene and Cloning of a Novel 5‐HT4 Splice Variant

M. Jurzak, J. Leysen, P. Verhasselt, 2000, Journal of neurochemistry.

Cloning and Expression of a Human Serotonin 5‐HT4 Receptor cDNA

M. Jurzak, J. Leysen, P. Verhasselt, 1997, Journal of neurochemistry.

Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor.

J. Leysen, H. Moereels, W. Luyten, 1993, Biochemical and biophysical research communications.

Identification of non-serotonergic [3H]ketanserin binding sites on human platelets and their role in serotonin release.

J. Leysen, P. Janssen, W. Gommeren, 1991, European journal of pharmacology.

Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone

J. Leysen, P. Janssen, R. Woestenborghs, 2004, Psychopharmacology.

Differential regulation of dopamine-D2 and serotonin-S2 receptors by chronic treatment with the serotonin-S2 antagonists, ritanserin, and setoperone.

J. Leysen, P. Laduron, W. Gommeren, 1987, Psychopharmacology series.

Impact of Janssen drugs for the identification of brain receptors

J. Leysen, P. Laduron, J. van Dun, 1986 .

Different kinetic properties of neuroleptic receptor binding in the rat striatum and frontal cortex.

J. Leysen, W. Gommeren, 1978, Life sciences.

Radiosynthesis of a new radioiodinated ligand for serotonin‐5HT2‐receptors, a promising tracer for γ‐emission tomography

J. Leysen, P. Janssen, J. Mertens, 1994 .

Drug‐receptor dissociation time, new tool for drug research: Receptor binding affinity and drug‐receptor dissociation profiles of serotonin‐S2, Dopamine‐D2, histamine‐H1 antagonists, and opiates

J. Leysen, W. Gommeren, 1986 .

Autoradiographic evidence for the occlusion of rat brain dopamine D3 receptors in vivo.

J. Leysen, W. Luyten, W. Gommeren, 1992, European journal of pharmacology.

In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole.

J. Leysen, P. Laduron, W. Gommeren, 1982, Molecular pharmacology.

[3H]Sufentanil, a superior ligand for mu-opiate receptors: binding properties and regional distribution in rat brain and spinal cord.

J. Leysen, C. Niemegeers, W. Gommeren, 1983, European journal of pharmacology.

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

P. F. M. Janssen, J. Leysen, W. Luyten, 1996, Psychopharmacology.

Demonstration of a complex subunit composition of a unitary dopamine receptor: effects of lesions and proteolytic enzymes on stereospecific binding.

J. Leysen, W. Gommeren, P. van Gompel, 1983, Advances in biochemical psychopharmacology.

Evaluation of radioiodo-4-amino-N-[1-[3-(4-fluorophenoxy)-propyl]-4- methyl-4-piperidinyl]-5-iodo-2-methoxybenzamide as a potential 5HT2 receptor tracer for SPE(C)T.

J. Leysen, P. Janssen, J. Mertens, 1995, Nuclear medicine and biology.

Tissue fractionation in rat brain, kidney and liver. I. Intracellular localization of a 5-methyltetrahydrofolic acid requiring enzyme.

P. Laduron, W. Gommeren, P. Janssen, 1975, Biochimie.

N-methylation of biogenic amines. I. Characterization and properties of an N-methyltransferase in rat brain using 5-methyltetrahydrofolic acid as the methyl donor.

J. Leysen, P. Laduron, W. Gommeren, 1974, Biochemical pharmacology.

Interaction of peptides and morphine-like narcotic analgesics with specifically labelled mu- and delta-opiate receptor binding sites.

J. Leysen, W. Gommeren, W. De Potter, 1983, Archives internationales de pharmacodynamie et de therapie.

Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

J. Leysen, P. Laduron, W. Gommeren, 1985, Molecular pharmacology.

Optimal Conditions for [3H]Apomorphine Binding and Anomalous Equilibrium Binding of [3H]Apomorphine and [3H]Spiperone to Rat Striatal Membranes: Involvement of Surface Phenomena Versus Multiple Binding Sites

J. Leysen, W. Gommeren, 1981, Journal of neurochemistry.

Spiperone: a ligand of choice for neuroleptic receptors. 1. Kinetics and characteristics of in vitro binding.

J. Leysen, P. Laduron, W. Gommeren, 1978, Biochemical pharmacology.

Comparative study of central and peripheral histamine‐H1 receptor binding in vitro and ex vivo of non‐sedating antihistamines and of noberastine, a new agent

W. Gommeren, P. Janssen, P. Janssen, 1991 .

Effects of lesions on 3H-apomorphine and 3H-spiperone stereospecific binding sites in subcellular fractions of rat striatum

J. Leysen, W. Gommeren, P. Gompel, 1981, Neurochemistry International.

Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs.

J. Leysen, P. Janssen, W. Gommeren, 1988, The Journal of pharmacology and experimental therapeutics.

Demonstration of S2-receptor binding sites on cat blood platelets using [3H]ketanserin.

J. Leysen, F. De Clerck, W. Gommeren, 1983, European journal of pharmacology.

Biochemical profile of risperidone, a new antipsychotic.

J. C. Stoof, J. Leysen, P. Janssen, 1988, The Journal of pharmacology and experimental therapeutics.

Binding of [3H]paroxetine to platelets of depressed patients: seasonal differences and effects of diagnostic classification.

J. Leysen, M. Maes, P. Cosyns, 1994, Journal of affective disorders.

Regional distribution of serotonin-2 receptor binding sites in the brain and effects of neuronal lesions.

J. Leysen, W. Gommeren, P. van Gompel, 1982, Archives internationales de pharmacodynamie et de therapie.

In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.

J. Leysen, P. Pauwels, P. Janssen, 1992, Molecular pharmacology.

The Receptor Binding Profile of the New Antihypertensive Agent Nebivolol and its Stereoisomers Compared with Various β-Adrenergic Blockers

J. Leysen, P. Janssen, P. Pauwels, 1988, Molecular pharmacology.

Comparison of in vitro binding properties of a series of dopamine antagonists and agonists for cloned human dopamine D2S and D2L receptors and for D2 receptors in rat striatal and mesolimbic tissues, using [125I] 2′-iodospiperone

P. Seeburg, J. Leysen, P. Pauwels, 2005, Psychopharmacology.

Non-serotonergic [3H]ketanserin binding sites in striatal membranes are associated with a dopac release system on dopaminergic nerve endings.

J. Leysen, P. Janssen, W. Gommeren, 1987, European journal of pharmacology.

Comparison of the In‐vitro Receptor Selectivity of Substituted Benzamide Drugs for Brain Neurotransmitter Receptors

J. Leysen, P. Jenner, P. Jenner, 1988, The Journal of pharmacy and pharmacology.

Mapping of serotonin 5‐HT4 receptor mRNA and ligand binding sites in the post‐mortem human brain

P. Bonaventure, M. Jurzak, J. Leysen, 2000, Synapse.

Binding properties of 3H-lofentanil at the opiate receptor.

J. Leysen, W. Gommeren, 1982, Archives internationales de pharmacodynamie et de therapie.

Stable, high-level expression of human serotonin receptors in L929 cells using an inducible expression system.

J. Leysen, G. Haegeman, W. Luyten, 1997, Receptors & channels.

Reconstitution of the human 5-HT(1D) receptor-G-protein coupling: evidence for constitutive activity and multiple receptor conformations.

M. Jurzak, J. Leysen, M. P. Castelli, 2000, Molecular pharmacology.

Efficient expression of neurotransmitter receptors in mammalian cells: use of inducible expression systems.

J. Leysen, G. Haegeman, W. Luyten, 1998, Annals of the New York Academy of Sciences.

Optimized expression of serotonin receptors in mammalian cells using inducible expression systems

J. Leysen, G. Haegeman, P. Vanhoenacker, 1999 .

Quantitative autoradiographic distribution of gamma-hydroxybutyric acid binding sites in human and monkey brain.

J. Leysen, X. Langlois, G. Gessa, 2000, Brain research. Molecular brain research.